A systematic review of 43 randomized trials involving more than 14,000 patients found that evidence shows several newer calcitonin gene–related peptide (CGRP)-targeted drugs can reduce chronic migraine frequency by about 2 headache days per month compared with placebo. In the review published in the Annals of Internal Medicine, researchers also found the CGRPs may achieve at least a 50% reduction in migraine frequency, although those findings were sourced from a limited number of studies. Botulinum …
Read More


